CRISPR Therapeutics AG CRSP
Caution (early) Health Tech sector · CRISPR Therapeutics — gene-editing pioneer with its first approved therapy, early commercially.
🗓 Reports earnings in 34 days (2026-11-09) — calendar context, not a prediction.
CRISPR Therapeutics AG (CRSP) is an early-stage Health Tech company, graded Caution (early) on FrontierLab's evidence-based quality rubric (data as of 2026-10-05). Gross-profits-to-assets is -0.08; Rule of 40 is -4035.7. Net share issuance 10.8% YoY (heavy issuance). 2 risk flags are noted below. Analyst mix: 17 buy / 11 hold / 0 sell. Track record: 27% of Early-stage-graded names beat the S&P over 63 sessions (95% CI 15–44%, N=33). Median excess vs the S&P was -14.6%.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | — |
|---|---|
| Gross margin | — |
| Gross profits / assets | -0.08 |
| Rule of 40 | -4035.7 |
| Net margin | -3971.5% |
| Cash runway (months) | 76.8 |
| PEG | — |
| Price / sales | 399.2 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ✗ Capital efficiency
- ✓ Share dilution — 10.8%
- ✗ Competitive moat — None
- ✓ Market size (TAM) — Large
Grade history
- 2026-08-07 — Caution (early) (from Promising (early))
- 2026-06-10 — Promising (early) (first graded)
Every grade change since FrontierLab began tracking this name — the receipts behind the current grade.
How have Early-stage-graded names performed?
The forward returns of all Early-stage-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 45% of Early-stage-graded names beat the S&P over 21 sessions (95% CI 29–62%, N=31). | Median excess vs the S&P was -3.2%. |
| ~3 months | 27% of Early-stage-graded names beat the S&P over 63 sessions (95% CI 15–44%, N=33). | Median excess vs the S&P was -14.6%. |
| ~6 months | building — 46 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| Burning cash — operating margin is negative. | 36 | -6.5% |
| Heavy dilution (~11%/yr) — top-decile share issuers have historically underperformed. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
Fundamentals
| Market cap | $5.35B |
|---|---|
| Stage | Early |
| Share issuance (YoY) | 10.8% · heavy issuance |
| Moat | None |
| TAM | LARGE |
| P/E (trailing) | — |
| EPS (trailing) | $-4.76 |
| Burn multiple | 27.6 |
| Gross-margin trend (pts) | — |
| Cash / assets | 0.89 |
| Accruals (%) | -3.5% |
| Net debt / EBITDA | — |
| Statements as of | Q2 FY2026 · filed 2026-08-03 |
Momentum context — describes the past, not a signal
Low reached Mar 30, 2026 · high reached Oct 8, 2025 — by daily close.
| Price | $55.43 (as of 2026-10-02) |
|---|---|
| Last session move | — |
| % off 52-wk high | -29.4% |
| RSI (14) | 51 |
| Relative volume | 0.7× |
Risk flags
Positive signals
Insider activity (90 days)
| Cluster buyers | 0 |
|---|---|
| Sellers | 2 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 6 |
|---|---|
| Buy | 11 |
| Hold | 11 |
| Sell | 0 |
| Strong sell | 0 |
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
Clinical data presentation scheduled; Anthropic AI comparison noted; temporary weakness mentioned.
- CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026
- Anthropic Just Made a CRISPR-Like Discovery. What It Actually Means for CRSP Stock Investors.
AI take — daily, AI-generated
AI leans cautious
Missing core metrics (growth, margins), negative GP/A, and 76.8-month runway suggest a cash-burn story masquerading as opportunity; clinical data is speculative and doesn't offset weak fundamentals.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Health Tech names
← All Health Tech names · Open CRSP in the interactive screener →
Data as of 2026-10-05 08:19 (end-of-day). How grades are computed →